Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

How Pharmacy Benefit Managers Add to Financial Toxicity: The Copay Accumulator Program.

Nabhan C, Phillips EG Jr, Feinberg BA.

JAMA Oncol. 2018 Oct 4. doi: 10.1001/jamaoncol.2018.4554. [Epub ahead of print] No abstract available.

PMID:
30286215
2.

Approaches to Chronic Lymphocytic Leukemia Therapy in the Era of New Agents: The Conundrum of Many Options.

Jain N, Thompson P, Ferrajoli A, Nabhan C, Mato AR, O'Brien S.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):580-591. doi: 10.1200/EDBK_200691.

3.

Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.

Mato AR, Roeker LE, Allan JN, Pagel JM, Brander DM, Hill BT, Cheson BD, Furman RR, Lamanna N, Tam CS, Handunnetti S, Jacobs R, Lansigan F, Bhavsar E, Barr PM, Shadman M, Skarbnik AP, Goy A, Beach DF, Svoboda J, Pu JJ, Sehgal AR, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Rhodes J, Ujjani CS, Nabhan C.

Am J Hematol. 2018 Nov;93(11):1394-1401. doi: 10.1002/ajh.25261. Epub 2018 Sep 26.

PMID:
30132965
4.

Barriers to Oncology Biosimilars Uptake in the United States.

Nabhan C, Valley A, Feinberg BA.

Oncologist. 2018 Jul 26. pii: theoncologist.2018-0066. doi: 10.1634/theoncologist.2018-0066. [Epub ahead of print] No abstract available.

PMID:
30049886
5.

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.

Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Goy A, Winter AM, Garcia C, Kennard K, Isaac K, Dorsey C, Gashonia LM, Singavi AK, Roeker LE, Zelenetz A, Williams A, Howlett C, Weissbrot H, Ali N, Khajavian S, Sitlinger A, Tranchito E, Rhodes J, Felsenfeld J, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Svoboda J, Furman RR, Nabhan C.

Haematologica. 2018 Sep;103(9):1511-1517. doi: 10.3324/haematol.2018.193615. Epub 2018 Jun 7.

6.

Biosimilars.

Parsad S, Nabhan C.

JAMA Oncol. 2018 Jul 1;4(7):1023. doi: 10.1001/jamaoncol.2018.0999. No abstract available.

PMID:
29879276
7.

Using response evaluation criteria in solid tumors in real-world evidence cancer research.

Feinberg BA, Bharmal M, Klink AJ, Nabhan C, Phatak H.

Future Oncol. 2018 May 31. doi: 10.2217/fon-2018-0317. [Epub ahead of print]

PMID:
29848070
8.

Fulfillment of Postmarketing Requirements to the FDA for Therapies Granted Oncology Indications Between 2011 and 2016.

Zettler M, Nabhan C.

JAMA Oncol. 2018 Jul 1;4(7):993-994. doi: 10.1001/jamaoncol.2018.0610. No abstract available.

PMID:
29801111
9.

Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611).

Tallarico M, Foster JC, Seisler D, Lafky JM, Hurria A, Jatoi A, Cohen HJ, Muss HB, Bartlett N, Cheson BD, Jung SH, Leonard JP, Byrd JC, Nabhan C.

J Geriatr Oncol. 2018 Jul;9(4):321-328. doi: 10.1016/j.jgo.2018.03.018. Epub 2018 Apr 17.

10.

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.

Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ.

J Clin Oncol. 2018 May 10;36(14):1389-1395. doi: 10.1200/JCO.2017.76.4381. Epub 2018 Mar 28.

PMID:
29590007
11.

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.

Mato AR, Nabhan C, Thompson MC, Lamanna N, Brander DM, Hill B, Howlett C, Skarbnik A, Cheson BD, Zent C, Pu J, Kiselev P, Goy A, Claxton D, Isaac K, Kennard KH, Timlin C, Landsburg D, Winter A, Nasta SD, Bachow SH, Schuster SJ, Dorsey C, Svoboda J, Barr P, Ujjani CS.

Haematologica. 2018 May;103(5):874-879. doi: 10.3324/haematol.2017.182907. Epub 2018 Feb 1.

12.

Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect® CLL cohort study.

Flowers CR, Nabhan C, Kay NE, Mato A, Lamanna N, Farber CM, Davids MS, Kiselev P, Swern AS, Sullivan K, Flick ED, Sharman JP.

Leuk Lymphoma. 2018 Feb 7:1-9. doi: 10.1080/10428194.2018.1427860. [Epub ahead of print]

PMID:
29415595
13.

Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry.

Mato A, Nabhan C, Kay NE, Lamanna N, Kipps TJ, Grinblatt DL, Flowers CR, Farber CM, Davids MS, Kiselev P, Swern AS, Bhushan S, Sullivan K, Flick ED, Sharman JP.

Clin Lymphoma Myeloma Leuk. 2018 Feb;18(2):114-124.e2. doi: 10.1016/j.clml.2017.11.010. Epub 2017 Dec 6.

14.

Two Doctors, One Patient, and a Common Goal.

Nabhan C, Topin J.

Oncologist. 2018 Apr;23(4):507-509. doi: 10.1634/theoncologist.2017-0554. Epub 2018 Jan 19. No abstract available.

15.

Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.

Janiga J, Kentley J, Nabhan C, Abdulla F.

Leuk Lymphoma. 2018 Mar;59(3):562-577. doi: 10.1080/10428194.2017.1347650. Epub 2018 Jan 8.

PMID:
29308723
16.

Early progression of disease as a predictor of survival in chronic lymphocytic leukemia.

Ahn IE, Farber CM, Davids MS, Grinblatt DL, Kay NE, Lamanna N, Mato A, Nabhan C, Kiselev P, Swern AS, Flick ED, Sullivan K, Sharman JP, Flowers CR.

Blood Adv. 2017 Nov 28;1(25):2433-2443. doi: 10.1182/bloodadvances.2017011262. eCollection 2017 Nov 28.

17.

Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL.

Kadri S, Lee J, Fitzpatrick C, Galanina N, Sukhanova M, Venkataraman G, Sharma S, Long B, Petras K, Theissen M, Ming M, Kobzev Y, Kang W, Guo A, Wang W, Niu N, Weiner H, Thirman M, Stock W, Smith SM, Nabhan C, Segal JP, Lu P, Wang YL.

Blood Adv. 2017 May 2;1(12):715-727. doi: 10.1182/bloodadvances.2016003632. eCollection 2017 May 9.

18.

Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia.

Mato AR, Clasen S, Pickens P, Gashonia L, Rhodes J, Svoboda J, Hughes M, Nabhan C, Ali N, Schuster S, Carver J.

Cancer Biol Ther. 2018 Jan 2;19(1):1-2. doi: 10.1080/15384047.2017.1394554. Epub 2017 Dec 27.

PMID:
29281559
19.

Behavioral Economics and the Future of Biosimilars.

Nabhan C, Feinberg BA.

J Natl Compr Canc Netw. 2017 Dec;15(12):1449-1451. doi: 10.6004/jnccn.2017.7023. No abstract available.

PMID:
29223980
20.

Challenges, Perceptions, and Readiness of Oncology Clinicians for the MACRA Quality Payment Program.

Nabhan C, Jeune-Smith Y, Klinefelter P, Kelly RJ, Feinberg BA.

JAMA Oncol. 2018 Feb 1;4(2):252-253. doi: 10.1001/jamaoncol.2017.3773. No abstract available.

PMID:
29167859
21.

MACRA in Oncology Care: Are We Ready?

Nabhan C, Tchafa A, Feinberg BA.

J Oncol Pract. 2017 Dec;13(12):777-779. doi: 10.1200/JOP.2017.025767. Epub 2017 Nov 16. No abstract available.

PMID:
29144865
22.

RAISE Act or Reduce Act?

Nabhan C.

JAMA Oncol. 2018 Jan 1;4(1):23-24. doi: 10.1001/jamaoncol.2017.3766. No abstract available.

PMID:
29098265
23.

Chimeric Antigen Receptor T-Cell Therapy for Chronic Lymphocytic Leukemia: A Narrative Review.

Mato AR, Thompson MC, Nabhan C, Svoboda J, Schuster SJ.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):852-856. doi: 10.1016/j.clml.2017.07.007. Epub 2017 Jul 21. Review.

PMID:
28826693
24.

Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents: A Review.

Thompson M, Brander D, Nabhan C, Mato A.

JAMA Oncol. 2018 Mar 1;4(3):394-400. doi: 10.1001/jamaoncol.2017.2009.

PMID:
28750119
25.

Biosimilars in Oncology in the United States: A Review.

Nabhan C, Parsad S, Mato AR, Feinberg BA.

JAMA Oncol. 2018 Feb 1;4(2):241-247. doi: 10.1001/jamaoncol.2017.2004.

PMID:
28727871
26.

Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab.

Malecek MK, Petrich AM, Rozell S, Chu B, Trifilio S, Galanina N, Maurer M, Farooq U, Link BK, Nowakowski GS, Nabhan C, Ayed AO.

Am J Hematol. 2017 Nov;92(11):1156-1162. doi: 10.1002/ajh.24864. Epub 2017 Aug 17.

PMID:
28719025
27.

Emerging Strategies in Treating Double Hit Lymphomas.

Nabhan C, Mato AR.

Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):563-568. doi: 10.1016/j.clml.2017.06.017. Epub 2017 Jun 21. Review.

PMID:
28711572
28.

Value-Based Calculators in Cancer: Current State and Challenges.

Nabhan C, Feinberg BA.

J Oncol Pract. 2017 Aug;13(8):499-506. doi: 10.1200/JOP.2017.022947. Epub 2017 Jun 15. Review.

PMID:
28617618
29.

Economic Modeling of the Cost of Chronic Lymphocytic Leukemia Therapy: It Is About the Model.

Nabhan C, Mato AR.

J Clin Oncol. 2017 Jun 1;35(16):1863-1864. doi: 10.1200/JCO.2016.71.9690. Epub 2017 Mar 13. No abstract available.

PMID:
28549225
30.

Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.

Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, Winter AM, Cruz AL, Claxton DF, Goy A, Daniel C, Isaac K, Kennard KH, Timlin C, Fanning M, Gashonia L, Yacur M, Svoboda J, Schuster SJ, Nabhan C.

Ann Oncol. 2017 May 1;28(5):1050-1056. doi: 10.1093/annonc/mdx031.

PMID:
28453705
31.

Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States.

Nabhan C, Mato A, Flowers CR, Grinblatt DL, Lamanna N, Weiss MA, Davids MS, Swern AS, Bhushan S, Sullivan K, Flick ED, Kiselev P, Sharman JP.

BMC Cancer. 2017 Mar 16;17(1):198. doi: 10.1186/s12885-017-3176-x.

32.

CAR-T cells: the next era in immuno-oncology.

Feinberg BA, Fillman J, Simoncini J, Nabhan C.

Am J Manag Care. 2017 Feb;23(2 Spec No.):SP48-SP52. No abstract available.

33.

Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study.

Mato AR, Timlin C, Ujjani C, Skarbnik A, Howlett C, Banerjee R, Nabhan C, Schuster SJ.

Br J Haematol. 2018 Apr;181(2):259-261. doi: 10.1111/bjh.14540. Epub 2017 Feb 21. No abstract available.

PMID:
28220935
34.

Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma.

Karmali R, Nabhan C, Petrich AM, Raizer J, Peace D, Lukas R, Gordon LI, Basu S, Chukkapalli V, Venugopal P.

Br J Haematol. 2017 Apr;177(1):72-79. doi: 10.1111/bjh.14522. Epub 2017 Feb 17.

PMID:
28211579
35.

Lean: Targeted Therapy for Care Delivery.

Nabhan C, Horner G, Howell MD.

J Natl Compr Canc Netw. 2017 Feb;15(2):271-274. No abstract available.

PMID:
28188193
36.

Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study.

Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, Calzada O, Cohen JB, Farmer L, Ghosh N, Tallarico M, Nabhan C, Costa LJ, Kenkre VP, Hari PN, Fenske TS.

Hematol Oncol. 2017 Dec;35(4):528-535. doi: 10.1002/hon.2380. Epub 2017 Jan 8.

PMID:
28066928
37.

Real-world clinical experience in the Connect® chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres.

Mato A, Nabhan C, Kay NE, Weiss MA, Lamanna N, Kipps TJ, Grinblatt DL, Flinn IW, Kozloff MF, Flowers CR, Farber CM, Kiselev P, Swern AS, Sullivan K, Flick ED, Sharman JP.

Br J Haematol. 2016 Dec;175(5):892-903. doi: 10.1111/bjh.14332. Epub 2016 Nov 8.

38.

Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.

Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, Strelec LE, Vandegrift A, Fitzpatrick DM, Zent CS, Feldman T, Goy A, Claxton DF, Bachow SH, Kaur G, Svoboda J, Nasta SD, Porter D, Landsburg DJ, Schuster SJ, Cheson BD, Kiselev P, Evens AM.

Blood. 2016 Nov 3;128(18):2199-2205. Epub 2016 Sep 6.

39.

Clinical pathways in chronic lymphocytic leukemia: Challenges and solutions.

Nabhan C, Mato AR, Feinberg BA.

Am J Hematol. 2017 Jan;92(1):5-6. doi: 10.1002/ajh.24589. Epub 2016 Nov 18. Review. No abstract available.

40.

Ambulatory Oncology Operations: Strategies to Alleviate Complexity.

Nabhan C, Parsad S.

J Natl Compr Canc Netw. 2016 Oct;14(10):1329-1331. No abstract available.

PMID:
27697985
41.

Interim PET Scans in Diffuse Large B-Cell Lymphoma: Is It Ready for Prime Time?

Bolshinsky M, Nabhan C.

Clin Lymphoma Myeloma Leuk. 2016 Dec;16(12):655-661. doi: 10.1016/j.clml.2016.08.020. Epub 2016 Sep 8. Review.

PMID:
27693134
42.

When "Rocking the Boat" Saves a Life.

Nabhan C.

JAMA Oncol. 2017 Apr 1;3(4):445. doi: 10.1001/jamaoncol.2016.3043. No abstract available.

PMID:
27632421
43.

Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.

Landsburg DJ, Falkiewicz MK, Petrich AM, Chu BA, Behdad A, Li S, Medeiros LJ, Cassaday RD, Reddy NM, Bast MA, Vose JM, Kruczek KR, Smith SE, Patel P, Hernandez-Ilizaliturri F, Karmali R, Rajguru S, Yang DT, Maly JJ, Blum KA, Zhao W, Vanslambrouck C, Nabhan C.

Br J Haematol. 2016 Nov;175(4):631-640. doi: 10.1111/bjh.14282. Epub 2016 Jul 29.

44.

Ofatumumab monotherapy in relapsed/refractory diffuse large B-cell non-Hodgkin lymphoma.

Galanina N, Jasielec J, Peace D, Smith SM, Nabhan C.

Leuk Lymphoma. 2017 Mar;58(3):752-753. doi: 10.1080/10428194.2016.1207764. Epub 2016 Jul 14. No abstract available.

PMID:
27415580
45.

Surveillance Imaging in Patients in Remission From Hodgkin and Diffuse Large B-Cell Lymphoma.

Nabhan C, Smith SM, Cifu AS.

JAMA. 2016 May 17;315(19):2115-6. doi: 10.1001/jama.2016.4913. No abstract available.

PMID:
27187305
46.

Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States.

Nabhan C, Zhou X, Day BM, Dawson K, Zelenetz AD, Friedberg JW, Cerhan JR, Link BK, Flowers CR.

Am J Hematol. 2016 Aug;91(8):770-5. doi: 10.1002/ajh.24401. Epub 2016 May 24.

47.

Use of class I histone deacetylase inhibitor romidepsin in combination regimens.

Petrich A, Nabhan C.

Leuk Lymphoma. 2016 Aug;57(8):1755-65. doi: 10.3109/10428194.2016.1160082. Epub 2016 Apr 27. Review.

48.

Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemia.

Nabhan C, Chaffee KG, Slager SL, Galanina N, Achenbach SJ, Schwager SM, Kay NE, Shanafelt TD.

Am J Hematol. 2016 Jul;91(7):677-80. doi: 10.1002/ajh.24374. Epub 2016 Apr 24.

49.

The evolving role of lenalidomide in non-Hodgkin lymphoma.

Galanina N, Petrich A, Nabhan C.

Leuk Lymphoma. 2016 Jul;57(7):1507-16. doi: 10.3109/10428194.2016.1146949. Epub 2016 Feb 22. Review.

PMID:
26902680
50.

Oncology Pathways-Preventing a Good Idea From Going Bad.

Polite BN, Page RD, Nabhan C.

JAMA Oncol. 2016 Mar;2(3):297-8. doi: 10.1001/jamaoncol.2015.5778. No abstract available.

PMID:
26847876

Supplemental Content

Loading ...
Support Center